Skip to content
    BFRI
    Earnings call· Jun 2026(Q2 FY26)

    Biofrontera Q2 FY26 earnings call BFRI

    Aug 13, 2026 Source

    Executive summary

    Biofrontera Q2 FY26 — Strong Revenue Growth and Path to Profitability

    Biofrontera delivered its strongest second quarter and first half as a standalone U.S. business, driven by robust Ameluz sales and significantly improved gross margins following a strategic transaction. Despite an ITC ruling impacting the RhodoLED XL lamp, the company is pursuing remediation and legal avenues while focusing on pipeline advancements for superficial basal cell carcinoma and actinic keratosis label expansion to drive future growth through its existing commercial infrastructure.

    Highlights

    5

    • Net product revenue grew 33% to $12 million in Q2 FY26, marking the strongest Q2 in company history.

    • Gross margin reached approximately 80% in Q2 FY26, an expansion of 920 basis points year-over-year.

    • Adjusted EBITDA was near breakeven at negative $0.2 million in Q2 FY26, a $5 million improvement from Q2 FY25.

    • Ameluz unit volume increased approximately 30% to 33,300 tubes sold in Q2 FY26.

    • FDA accepted the sNDA filing for Ameluz PDT for superficial basal cell carcinoma (sBCC) with a PDUFA target date of September 28, 2026.

    Concerns

    3

    • The International Trade Commission (ITC) issued a limited exclusion order and cease and desist orders, restricting import/sale of the RhodoLED XL lamp and Ameluz for use with it, effective July 7.

    • Cash and cash equivalents decreased to $4.7 million as of June 30, 2026, from $6.4 million at December 31, 2025.

    • The company's financial statements include a going concern qualification.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full year 2026 revenue goals
    Maintain full year 2026 revenue goals
    high materiality
    High
    PDUFA target date for Ameluz PDT for superficial basal cell carcinoma
    September 28, 2026
    high materiality
    High
    Launch of Ameluz PDT for superficial basal cell carcinoma
    Q1 2027
    high materiality
    High
    sNDA filing for Ameluz label expansion (AK on extremities, neck, trunk)
    Around the end of Q3 2026
    medium materiality
    High
    FDA approval for Ameluz label expansion (AK on extremities, neck, trunk)
    Q3 2027
    medium materiality
    Medium
    Cash flow breakeven
    Achieve this year
    high materiality
    Medium

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    Dermatology (Ameluz)
    Ameluz net product revenue growth was driven by strong unit volume and a price increase. Commercial execution metrics indicate robust underlying demand and effective sales strategies. The installed lamp base continues to grow, supporting future product launches.
    Ameluz unit volume: 33,300 tubes (Q2 FY26)Ameluz unit volume growth: 30% (Q2 FY26 vs Q2 FY25)Price increase impact: Implemented Q4 2025Installed lamp base: 801 lamps (across 740 physician offices)RhodoLED lamp placements: 21 lamps (Q2 FY26, including 16 XL and 5 RhodoLED)Order count growth: 18.6% (H1 FY26 vs H1 FY25)Average tubes per order growth: 10% (H1 FY26)Large customer reorder rate: 81% (H1 FY26)Large customer Ameluz volume growth: 41% (H1 FY26, for reordering customers)New account additions: 66 (H1 FY26)Inside sales Ameluz tubes from whitespace: 1,070 tubes (H1 FY26)Inside sales Ameluz tubes from vacant territories: 920 tubes (H1 FY26)
    		$12.0M33%——

    Operational metrics

    28
    Adjusted EBITDA
    -$0.2Mvs -$5.1M in Q2 FY25
    Q2 FY26

    Near breakeven, representing a $5 million improvement year-over-year.

    Adjusted EBITDA
    -$3.7Mvs -$9.5M in H1 FY25
    H1 FY26

    Improved from prior year.

    Adjusted EBITDA margin
    -1.4%vs -56.9% in Q2 FY25
    Q2 FY26

    Significant margin expansion.

    Adjusted EBITDA margin
    -16.9%vs -54% in H1 FY25
    H1 FY26

    Significant margin expansion.

    Net product revenue
    $12.0Mvs $9.0M in Q2 FY25
    Q2 FY26

    Strongest operating Q2 in company history.

    Net product revenue growth
    32.9%YoY
    Q2 FY26

    Driven by Ameluz unit volume growth and price increase.

    Net product revenue
    $22.1Mvs $17.6M in H1 FY25
    H1 FY26

    Strongest H1 in company history.

    Net product revenue growth
    25.4%YoY
    H1 FY26

    Driven by Ameluz unit volume growth and price increase.

    Ameluz unit volume
    33,300 tubesvs 25,300 tubes in Q2 FY25
    Q2 FY26

    Volume growth included impact of order timing from customers anticipating ITC supply restrictions.

    Gross margin
    80%vs 71% in Q2 FY25
    Q2 FY26

    Improvement driven by transition from prior transfer pricing agreements to a 12% earn-out on net revenue.

    Gross margin
    80%vs 67% in H1 FY25
    H1 FY26

    Improvement driven by new cost structure.

    Cost of revenue
    $2.4Mvs $2.6M in Q2 FY25
    Q2 FY26

    Decreased year-over-year.

    Selling, general, and administrative expenses
    $9.7Mvs $10.6M in Q2 FY25
    Q2 FY26

    Decreased year-over-year, partially due to lower litigation-related legal fees.

    Selling, general, and administrative expenses
    $20.7Mvs $19.3M in H1 FY25
    H1 FY26

    Increased primarily due to investment, lower turnover in commercial organization, and new manufacturing/regulatory functions.

    Research and development expenses
    $0.4Mvs $0.9M in Q2 FY25
    Q2 FY26

    Reflecting current vintage of clinical trials reaching substantial completion.

    Research and development expenses
    $1.3Mvs $2.1M in H1 FY25
    H1 FY26

    Reflecting current vintage of clinical trials reaching substantial completion.

    Net loss (GAAP)
    $0.6Mvs $5.3M in Q2 FY25
    Q2 FY26

    GAAP net loss, significantly reduced year-over-year.

    Net loss per share (GAAP)
    $0.05vs $0.57 in Q2 FY25
    Q2 FY26

    GAAP net loss per share, significantly reduced year-over-year.

    Net loss (GAAP)
    $5.4Mvs $9.5M in H1 FY25
    H1 FY26

    GAAP net loss, significantly reduced year-over-year.

    Net loss per share (GAAP)
    $0.44vs $1.05 in H1 FY25
    H1 FY26

    GAAP net loss per share, significantly reduced year-over-year.

    Cash and cash equivalents
    $4.7Mvs $6.4M at Dec 31, 2025
    as of Jun 30, 2026

    Reflects operating cash usage and one-time paydown of related party payables.

    Operating cash used
    $1.7Mdown from $7.2M in H1 FY25
    H1 FY26

    Includes a $3.7M one-time paydown of related party payables in Q1 FY26.

    Total liabilities
    $18.1Messentially unchanged from Dec 31, 2025
    as of Jun 30, 2026

    Stable balance sheet.

    Outstanding indebtedness (convertible notes)
    $4.6M
    as of Jun 30, 2026

    No bank or term debt.

    Total shareholders' equity
    $6.0Mvs $10.5M at Dec 31, 2025
    as of Jun 30, 2026

    Decreased from year-end.

    RhodoLED XL lamps in installed base
    243
    as of Q2 FY26

    Part of the total 801 lamps, affected by ITC ruling.

    ITC remediation cost estimate
    $500,000
    Q1 FY26

    Recorded as best estimate in Q1, unchanged.

    Next milestone payment from XEPI divestiture
    $1.0M
    future

    Expected to contribute to liquidity.

    Industry KPIs

    7
    MetricValueDetails
    Prescription volume33,300tubes
    EPS revenue guidanceMaintain full year 2026 revenue goals
    Product franchise net sales$12.0MUSD
    Pipeline clinical milestones—
    Regulatory approvals filings—
    Price volume mix decomposition30%%
    Clinical trial efficacy safety data58%%

    Deals & partnerships

    1
    Biofrontera AG (prior parent company)Strategic transaction for full ownership of U.S. rights, approvals, and patents for Ameluz and RhodoLED portfolio.

    Completed in October 2025, giving Biofrontera Inc. full control over its key assets in the U.S.

    Risks & headwinds

    4
    International Trade Commission (ITC) limited exclusion orderOngoing

    Restricts import/sale of RhodoLED XL lamp and Ameluz for use with it, effective July 7.

    Mitigation: Remediation plan for a modified XL lamp (minor changes, FDA CBE-30 approval, awaiting border control agreement); ongoing legal appeal to Federal Circuit. Many customers bought inventory to bridge the gap.

    Going concern qualificationNear-term

    Company's financial statements include a going concern qualification.

    Mitigation: Continued growth of Ameluz revenue, realization of $1 million milestone payment from XEPI divestiture, and securing a working capital line of credit if necessary. Progress towards cash flow breakeven in 2026.

    R&D expenses dependent on available fundsComing years

    Future clinical developments for product expansion are dependent on available funds.

    Mitigation: Planning additional clinical developments, but subject to financial resources.

    Litigation-related legal spend variabilityOngoing

    Legal spend can vary quarter to quarter.

    Mitigation: Tied to the pace of active matters.

    What to watch in Q3 FY26

    5

    sBCC PDUFA Decision

    Q3 FY26
    CurrentPDUFA target date: September 28, 2026
    TargetFDA approval for Ameluz PDT for sBCC

    Why it matters

    Approval would make Ameluz the first PDT in the US for cancerous skin tumors and enable launch in Q1 2027, a significant growth driver.

    The FDA accepted filing of our supplemental New Drug Application for Ameluz PDT for the treatment of superficial basal cell carcinoma with a PDUFA target date of September 28, 2026.

    Q&A highlights

    5

    What steps are needed for the sBCC launch, beyond fitting existing call points and lamps, such as reimbursement and sales force training?

    The company needs to finalize marketing materials, pre-clear them with the FDA, train the sales force, and finalize the reimbursement strategy. The existing infrastructure is largely in place.

    “The actions that really need to be taken place to get ready for this launch are to finalize our marketing materials, pre-clear those with the FDA, and train our sales force, and then finalize our reimbursement strategy as well.”

    asked by Bruce Jackson · answered by George Jones

    2 min read4 chapters

    Detailed Narrative

    01

    ITC Matter and Remediation Plan

    The International Trade Commission (ITC) issued a final determination finding a violation of Section 337 regarding two Sun Pharmaceutical patents covering components of the RhodoLED XL lamp. This resulted in a limited exclusion order and cease and desist orders, effective July 7, preventing the import or sale of the current RhodoLED XL lamp and restricting Ameluz sales for use with it. The company recorded approximately $500,000 in Q1 FY26 as an estimate for remediation costs. Biofrontera is implementing a remediation plan involving minor changes to the XL lamp to operate outside the scope of the patents, which has received FDA approval via a CBE-30 process, and is awaiting border control agreement. The company retains the right to appeal the ITC decision to the Federal Circuit.

    02

    Strategic Transaction Impact on Gross Margin

    The strategic transaction completed in October 2025, which gave Biofrontera full ownership and control of all U.S. rights, approvals, and patents for the Ameluz and RhodoLED portfolio, significantly improved the company's gross margin. This transaction replaced a prior transfer pricing model of 25% to 35% of revenue with a 12% earn-out on net sales, contributing to the gross margin expansion from approximately 71% in Q2 FY25 to 80% in Q2 FY26.

    03

    Commercial Execution and Customer Dynamics

    Commercial execution showed significant traction, with order count up 18.6% and average tubes per order up 10% in H1 FY26 compared to H1 FY25. Over 81% of large customers who made purchases prior to the Q4 2025 price increase placed additional orders in H1 FY26, with their Ameluz volume increasing by 41%. New account additions were 66 in H1 FY26, a slight dip from 69 in H1 FY25, attributed to focus on existing XL customers prior to ITC orders. Inside sales efforts generated approximately 1,070 tubes of Ameluz from whitespace and smaller accounts, and another 920 tubes from covering vacant territories in H1 FY26.

    04

    Clinical Pipeline as Future Growth Driver

    The company's growth strategy for 2027 and beyond is centered on expanding approved uses for Ameluz through its clinical pipeline. This includes the expected launch of Ameluz PDT for superficial basal cell carcinoma in Q1 2027, anticipated FDA approval for actinic keratosis label extensions to extremities, neck, and trunk in Q3 2027, and the advancement of an acne program towards Phase III. These new indications are designed to leverage the existing installed lamp base, customer base, and sales force, minimizing additional infrastructure costs.

    AI-generated summary of the company’s earnings call. Not investment advice.